Bezabhe, WM and Bereznicki, LR and Radford, J and Wimmer, BC and Salahudeen, MS and Bindoff, I and Garrahy, E and Peterson, GM, Five-year trends in potential drug interactions with direct-acting oral anticoagulants in patients with atrial fibrillation: an Australian-wide study, Journal of Clinical Medicine, 9, (11) Article 3568. ISSN 2077-0383 (2020) [Refereed Article]
Copyright 2020 The Authors. Licensed under Creative Commons Attribution 4.0 International (CC BY 4.0) https://creativecommons.org/licenses/by/4.0/
Background: Co-prescribing medications that can interact with direct-acting oral anticoagulants (DOACs) may decrease their safety and efficacy. The aim of this study was to examine the co-prescribing of such medications with DOACs using the Australian national general practice dataset, MedicineInsight, over a five-year period.
Methods: We performed five sequential cross-sectional analyses in patients with atrial fibrillation (AF) and a recorded DOAC prescription. Patients were defined as having a drug interaction if they had a recorded prescription of an interacting medication while they had had a recorded prescription of DOAC in the previous six months. The sample size for the cross-sectional analyses ranged from 5333 in 2014 to 19,196 in 2018.
Results: The proportion of patients who had potential drug interactions with a DOAC decreased from 45.9% (95% confidence interval (CI) 44.6%–47.4%) in 2014 to 39.9% (95% CI 39.2%–40.6%) in 2018, p for trend < 0.001. During this period, the most frequent interacting class of medication recorded as having been prescribed with DOACs was selective serotonin/serotonin and norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants, followed by non-steroidal anti-inflammatory drugs (NSAIDs), calcium channel blockers (CCBs) and amiodarone.
Conclusions: Overall, potential drug interactions with DOACs have decreased slightly over the last five years; however, the rate of possible interaction with SSRIs/SNRIs has remained relatively unchanged and warrants awareness-raising amongst prescribers.
|Item Type:||Refereed Article|
|Keywords:||atrial fibrillation, direct-acting oral anticoagulants, drug–drug interactions, primary care|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Pharmacology and pharmaceutical sciences|
|Research Field:||Clinical pharmacology and therapeutics|
|Objective Group:||Other health|
|Objective Field:||Other health not elsewhere classified|
|UTAS Author:||Bezabhe, WM (Dr Woldesellassie Bezabhe)|
|UTAS Author:||Bereznicki, LR (Professor Luke Bereznicki)|
|UTAS Author:||Radford, J (Associate Professor Jan Radford)|
|UTAS Author:||Wimmer, BC (Dr Barbara Wimmer)|
|UTAS Author:||Salahudeen, MS (Dr Mohammed Salahudeen)|
|UTAS Author:||Bindoff, I (Dr Ivan Bindoff)|
|UTAS Author:||Garrahy, E (Dr Edward Garrahy)|
|UTAS Author:||Peterson, GM (Professor Gregory Peterson)|
|Web of Science® Times Cited:||2|
|Downloads:||1 View Download Statistics|
Repository Staff Only: item control page